Biotech Startups

Accutar Biotech applies artificial intelligence to drug discovery, using a hybrid approach of computational drug design followed by wet lab validation to reduce the time and cost of developing new drugs. The U.S.-based company models the physical and chemical properties of biological systems.

2 investors

Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing. The biotech company focuses on drug therapies as a first-line or complementary option to hearing aids and cochlear implants.

2 investors

Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.

2 investors

ACT Genomics is a cancer genomics company that provides genomic testing solutions to support personalized cancer care and precision medicine for patients and clinicians. Founded in 2014 as a member of the Delta Group, it focuses on the Taiwanese and broader Asian markets.

2 investors

Actipulse Neuroscience develops non-invasive brain stimulation technologies using high-frequency magnetic pulses to treat central nervous system disorders, including major depressive disorder and neurodegenerative diseases. The company conducts clinical research on transcranial neuromodulation devices.

2 investors

ActX provides Actionable Genomics, an evidence-based genetic analysis service covering medication use and hereditary disease risk, aimed at making precision medicine a standard of care. It serves patients, physicians, and health systems by integrating genetic risk information into clinical care.

2 investors

A pharmaceutical company focused on supplying medicines and improving access to high-quality drugs, offering branded originator drugs, authorized generics, complex generics, and other generic medicines. It operates globally with expertise in science, medical, and manufacturing, and this page covers its Japan product offerings.

2 investors

Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.

2 investors

AcuraStem is a biotechnology company developing antisense oligonucleotide treatments for neurodegenerative diseases such as ALS and frontotemporal dementia, using its iNeuroRx technology platform for disease modeling and drug discovery. It targets PIKFYVE, discovered by its co-founders, to advance a pipeline of therapies.

2 investors

Oorstec (Guangdong Oorstec Micro-Nano Technology) develops a digital microfluidics platform based on proprietary active-pixel thin-film semiconductor arrays that generates and manipulates large numbers of microscale biological droplets in parallel. Its technology serves life-science research, enabling high-throughput screening, discovery, and functional studies at the single microbe, cell, and molecule level.

2 investors

Cascade is an AI coordination platform for architecture, engineering, and construction firms that automates business development by analyzing unstructured project opportunities, scoring them for firm fit, and streamlining the pursuit-to-delivery cycle. The platform learns from each customer interaction to improve recommendations and turns the construction industry's relationship-driven sales process into a systematic, data-driven approach.

2 investors

Adamo Foods develops meat alternatives using a proprietary fermentation technology, producing fungi-based (mycelium) steaks and fillets. The company sells its plant-based products to restaurants.

2 investors

ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses. The company focuses on enabling biotherapeutics that would otherwise face prohibitive immunogenicity.

2 investors

Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.

2 investors

AdipoPharma is a biotech company developing therapies based on the endocrine biology of adipose tissue and targeted rare genetic disorders. Founded in 2022 (formerly ALMS Therapeutics), its work relates to metabolic diseases such as diabetes and obesity.

2 investors

Adiposs develops ImageBAT, a contrast agent for medical imaging of brown fat that can identify patients at increased cancer risk and with higher treatment failure risk. The product serves oncology and metabolic health markets.

2 investors

AdjuTec Pharma develops antibacterial technology targeting healthcare-associated infections, with a focus on Gram-negative bacterial infections in hospital and intensive-care settings. Its lead candidate, APC148, addresses the β-lactam and β-lactamase inhibitor market.

2 investors

Advarra provides clinical research services and technology, including institutional review board (IRB) and institutional biosafety committee (IBC) review, data monitoring, endpoint adjudication, and consulting, along with software platforms for clinical trials. It serves life sciences companies, research sites, and institutions in the clinical research industry.

2 investors

Advertent Biotherapeutics is a biotechnology company developing first-in-class biologics that modulate TGF-β family growth factors to protect muscle quality and promote regeneration in neuromuscular disorders, with a particular focus on muscular dystrophies. Founded in 2019 as a spin-out from Michigan State University, it targets high-unmet-need conditions where muscle degeneration and wasting cause disability.

2 investors

Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.

2 investors

Advion Interchim Scientific provides laboratory instruments, consumables, reagents, and software for chemical analysis and purification tasks such as chromatography, mass spectrometry, and ICP-MS. The company serves life science researchers and laboratories globally with identification, quantification, and purification solutions.

2 investors

Aegis operates a clinical laboratory providing definitive drug and substance testing services for healthcare providers, pharmaceutical companies, sports organizations, and corporations. The company offers medication monitoring, drug screening, and laboratory analytics integrated with electronic medical records systems.

2 investors

Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.

2 investors

AELIX Therapeutics is a company developing a therapeutic HIV vaccine intended for use in HIV cure and eradication strategies. It operates in the biotech and vaccine development sector.

2 investors